The Tumor Inflammation Score (TIS) (35), an 18-gene signature that measures pre-existing but suppressed adaptive immune response in cancers for putative sensitivity to PD-1/PDL-1 blockade, showed a range of scores consistent with those across the TCGA-PRAD cohort (75). The gene discussed is CD274; the disease is neoplasm.